Top Story
Press ReleaseAbbott Laboratories experienced a robust first quarter in 2024, driven primarily by its medical devices segment. This resulted in overall sales surpassing Wall Street forecasts and an updated, optimistic financial outlook for the year. The company reported a 2.2% increase in total sales year-over-year, reaching $10 [...]
Latest Stories
Integrated Evidence Assessment & Planning
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/18/2024 04:44 PM ET
Vertex Pharmaceuticals Incorporated VRTX date announcement
Vertex Pharmaceuticals Incorporated, makers of Suzetrigine (VX-548), will be announcing their top-line results for the drug's recent NDA Filing trial on August 31, 2024. Our calculations show a 70.7% chance that the drug makes [...]
Read More
04/18/2024 04:44 PM ET
Immutep Limited IMMP results announcement
Immutep Limited released new information about their Phase 1 trial for IMP761. Our analysts provided the following summary:
"Trial planned for mid-2024."
This is one of three upcoming announcements for the company.
The market was [...]
Read More
04/18/2024 04:44 PM ET
Benitec Biopharma BNTC date announcement
On August 31, 2024, Benitec Biopharma will announce top-line results for their recent Phase 1 trial for BB-301. Our calculations show a 65.1% chance that the drug makes it to the next stage.
The announcement [...]
Read More
04/18/2024 04:44 PM ET
NRX Pharmaceuticals OCUL date announcement
Ocular Therapeutix has an announcement scheduled for June 30, 2024 regarding their recent Phase 1 trial of AXPAXLI (OTX-TKI) - (HELIOS). Our predictive system gives the drug a 71.9% chance of making it to the [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
